Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.42 |
| ▸ | HTR1A | P08908 | 11/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411456 | 0.95 | HTR1A (0.43) | SLC6A4HTR1AEPHX2CCR3DDR1 | |
| SCHEMBL6410847 | 0.91 | SLC6A4 (0.46) | SLC6A4HTR1AKDM4EALDH1A1DDR1 | |
| SCHEMBL6418635 | 0.89 | HTR1A (0.46) | SLC6A4HTR1AEPHX2CCR3KDM4E | |
| SCHEMBL6413726 | 0.88 | SLC6A4 (0.43) | SLC6A4HTR1AEPHX2CCR3KDM4E | |
| SCHEMBL6412370 | 0.87 | SLC6A4 (0.43) | SLC6A4HTR1AEPHX2CCR3KDM4E | |
| SCHEMBL6412736 | 0.87 | HTR1A (0.53) | SLC6A4HTR1ACCR3 | |
| SCHEMBL6417556 | 0.86 | HTR1A (0.44) | SLC6A4HTR1AEPHX2CCR3KDM4E | |
| SCHEMBL6417194 | 0.86 | HTR1A (0.48) | SLC6A4HTR1AEPHX2CCR3KDM4E | |
| SCHEMBL6411147 | 0.86 | DRD2 (0.44) | SLC6A4HTR1AEPHX2CCR3KDM4E | |
| SCHEMBL6418316 | 0.85 | HTR1A (0.49) | SLC6A4HTR1ACCR3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1466901-A1 | SEROTONINE REUPTAKE INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | HTR1A, SLC6A4, SLC6A2 | SLC6A4 2/4885HTR1A 1/4885EPHX2 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.